Opendata, web and dolomites

BRAINSPECT

Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRAINSPECT project word cloud

Explore the words cloud of the BRAINSPECT project. It provides you a very rough idea of what is the project "BRAINSPECT" about.

isolate    flow    sensitive    hallmarks    bandwidth    scan    yield    plaques    imaging    molecular    ultra    route    tomography    reposition    radiation    times    reconstruction    animals    small    clinicians    modality    disrupt    dose    commercial    ring    accurate    artefacts    disturbed    initial    patient    resolution    progression    perfusion    spatial    assessing    proprietary    enthusiasm    point    worldwide    multibillion    pinholes    proven    measuring    neurotransmitter    uses    consuming    sparked    complete    radically    photon    clinical    computed    techniques    mentioned    market    sme    blood    imbalance    parts    stage    diagnosed    35    insufficient    utility    single    cerebral    sound    detection    mi    shorter    disease    stages    either    unprecedented    compensates    spect    strategy    validation    patients    feasibility    resolutions    instrument    prototype    lower    brain    amongst    regional    movement    characterising    multiple    milabs    costly    disorders    images    rcbf    time    figure    emission    indications    software    fold   

Project "BRAINSPECT" data sheet

The following table provides information about the project.

Coordinator
MILABS BV 

Organization address
address: Heidelberglaan 100 STR. 4.105
city: Utrecht
postcode: 3584 CX
website: www.milabs.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.milabs.com/g-spect/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MILABS BV NL (Utrecht) coordinator 50˙000.00

Map

 Project objective

MILabs’ radically new proprietary approaches for ultra-high resolution and ultra-sensitive brain SPECT (Single Photon Emission Computed Tomography) enable the measuring of disturbed regional cerebral blood flow (rCBF) perfusion, and characterising plaques and neurotransmitter imbalance - all important hallmarks of brain disorders - at unprecedented spatial resolutions. This new approach has the potential to disrupt the complete field of molecular imaging (MI), a multibillion market worldwide. Current techniques can only measure the mentioned effects in the brain either at late stages of disease progression (at which point the patients have already been diagnosed) or at insufficient resolution to isolate processes in small parts of the brain. Current SPECT results in low resolution images, are highly sensitive to patient movement and are time consuming and costly. MILabs has developed a clinical SPECT prototype, G-SPECT, which has proven its potential to reposition SPECT as the major clinical MI modality. G-SPECT uses a high bandwidth photon detection ring with multiple pinholes, and advanced reconstruction software that compensates for patient movement artefacts. This enables 35-fold higher resolution images, more accurate imaging and lower radiation dose due to shorter scan times (Figure 1). The application of MILabs SPECT technology in small animals has sparked enthusiasm amongst clinicians and brain researchers worldwide. In this Stage 1 SME Instrument, MILabs will investigate the commercial feasibility of this exciting technology by (i) identifying and assessing those indications to which the clinical utility yield the best initial market value, (ii) developing a sound clinical validation strategy and (iii) defining the route-to-market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSPECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSPECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More